For how we live.
Among 7,579 pregnancies in people with migraine, anti-CGRP antibody use early in pregnancy carried a 42% higher adjusted risk of spontaneous abortion; propranolol showed no increase. The data are observational.
TEMPLE, an AbbVie-funded phase 3b trial, is the first direct test of the CGRP blocker atogepant against topiramate — a long-used preventive many patients cannot tolerate.
A systematic review of human trials found the evidence weak and inconsistent. Where MSG seemed to trigger headaches, it was given in large doses dissolved in water without food, in studies that were not properly blinded.
A pooled analysis puts patient-reported rates at 13.9%, 8.0% and 12.0%. All of it is self-report, the heterogeneity is enormous, and the reviewers stop short of recommending avoidance.
The older oral preventives managed 0.44 to 1.4. The larger change is that the new drugs work in people the old ones failed, and are tolerated well enough to stay taken.
A new structured dataset finally makes the approvals countable. Two trials published weeks apart show why counting them says little: 0.86 fewer migraine days in one, a 20-point symptom shift in the other.